225 related articles for article (PubMed ID: 29112304)
1. The benefits of hepatitis C virus cure: Every rose has thorns.
Salmon D; Mondelli MU; Maticic M; Arends JE;
J Viral Hepat; 2018 Apr; 25(4):320-328. PubMed ID: 29112304
[TBL] [Abstract][Full Text] [Related]
2. What Comes First: Treatment of Viral Hepatitis or Liver Cancer?
Feld JJ; Krassenburg LAP
Dig Dis Sci; 2019 Apr; 64(4):1041-1049. PubMed ID: 30874985
[TBL] [Abstract][Full Text] [Related]
3. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
[TBL] [Abstract][Full Text] [Related]
4. The future of liver transplantation for viral hepatitis.
Durand F; Francoz C
Liver Int; 2017 Jan; 37 Suppl 1():130-135. PubMed ID: 28052618
[TBL] [Abstract][Full Text] [Related]
5. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
[TBL] [Abstract][Full Text] [Related]
6. Reversion of disease manifestations after HCV eradication.
van der Meer AJ; Berenguer M
J Hepatol; 2016 Oct; 65(1 Suppl):S95-S108. PubMed ID: 27641991
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
[TBL] [Abstract][Full Text] [Related]
8. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
9. Cure of HCV related liver disease.
Shiffman ML; Benhamou Y
Liver Int; 2015 Jan; 35 Suppl 1():71-7. PubMed ID: 25529090
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C cure with antiviral therapy--benefits beyond the liver.
Soriano V; Labarga P; Fernandez-Montero JV; de Mendoza C; Esposito I; Benítez-Gutiérrez L; Barreiro P
Antivir Ther; 2016; 21(1):1-8. PubMed ID: 26110692
[TBL] [Abstract][Full Text] [Related]
11. Benefits of hepatitis C cure with antivirals: why test and treat?
Lledó G; Benítez-Gutiérrez L; Arias A; Requena S; Cuervas-Mons V; de Mendoza C
Future Microbiol; 2019 Mar; 14():425-435. PubMed ID: 30900911
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies.
Origa R; Ponti ML; Filosa A; Galeota Lanza A; Piga A; Saracco GM; Pinto V; Picciotto A; Rigano P; Madonia S; Rosso R; D'Ascola D; Cappellini MD; D'Ambrosio R; Tartaglione I; De Franceschi L; Gianesin B; Di Marco V; Forni GL;
Am J Hematol; 2017 Dec; 92(12):1349-1355. PubMed ID: 28929515
[TBL] [Abstract][Full Text] [Related]
13. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
14. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients.
Laguno M; Larrousse M; Blanco JL; Leon A; Milinkovic A; Martínez-Rebozler M; Loncá M; Martinez E; Sanchez-Tapias JM; de Lazzari E; Gatell JM; Costa J; Mallolas J
AIDS Res Hum Retroviruses; 2008 Apr; 24(4):547-53. PubMed ID: 18393687
[TBL] [Abstract][Full Text] [Related]
16. Extrahepatic manifestations in chronic hepatitis C virus carriers.
Rosenthal E; Cacoub P
Lupus; 2015 Apr; 24(4-5):469-82. PubMed ID: 25801890
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
18. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular Carcinoma Occurrence and Recurrence after Antiviral Treatment in HCV-Related Cirrhosis. Are Outcomes Different after Direct Antiviral Agents? A Review.
Spârchez Z; Mocan T
J Gastrointestin Liver Dis; 2017 Dec; 26(4):403-410. PubMed ID: 29253056
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals.
Yeh ML; Huang CF; Hsieh MH; Ko YM; Chen KY; Liu TW; Lin YH; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CI; Huang JF; Kuo PL; Dai CY; Yu ML; Chuang WL
J Gastroenterol Hepatol; 2017 Oct; 32(10):1754-1762. PubMed ID: 28230928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
